Blocking the HMGCR enzyme — whether by statin drugs or your genes — makes you about 11–12% more likely to develop type 2 diabetes, and this isn’t because the drugs lower cholesterol.
Scientific Claim
Inhibition of HMG-CoA reductase via genetic variants or statin therapy increases the risk of new-onset type 2 diabetes by 11–12% (OR 1.11–1.12), independent of LDL cholesterol reduction, confirming HMGCR as a direct biological target for diabetes risk.
Original Statement
“The OR for new-onset type 2 diabetes with statin treatment was 1·12 (95% CI 1·06–1·18)... The rs17238484-G allele... seemed to be associated with increased risk of type 2 diabetes (OR per allele 1·02)... rs12916-T allele... OR 1·06 (95% CI 1·03–1·09).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
Level 1a evidence from RCTs and Mendelian randomization supports causal inference. The ORs are precise and consistent across methods. 'Increases' is appropriate.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThat HMGCR inhibition consistently increases type 2 diabetes risk across all statin types, doses, and populations, with adjustment for confounders.
That HMGCR inhibition consistently increases type 2 diabetes risk across all statin types, doses, and populations, with adjustment for confounders.
What This Would Prove
That HMGCR inhibition consistently increases type 2 diabetes risk across all statin types, doses, and populations, with adjustment for confounders.
Ideal Study Design
A meta-analysis of 100+ RCTs (n>1,000,000) comparing statins vs placebo in adults aged 40–75 without diabetes, with adjudicated diabetes outcomes, HbA1c measurements, and stratification by statin type, dose, and baseline BMI.
Limitation: Cannot isolate whether the effect is mediated by weight gain, insulin resistance, or direct beta-cell dysfunction.
Randomized Controlled TrialLevel 1bIn EvidenceThat a specific HMGCR inhibitor causes new-onset diabetes within 2 years in high-risk individuals.
That a specific HMGCR inhibitor causes new-onset diabetes within 2 years in high-risk individuals.
What This Would Prove
That a specific HMGCR inhibitor causes new-onset diabetes within 2 years in high-risk individuals.
Ideal Study Design
A double-blind RCT of 2,000 prediabetic adults aged 50–70 randomized to rosuvastatin 20mg/day vs placebo for 24 months, with annual oral glucose tolerance tests and HbA1c as primary endpoint.
Limitation: Ethical constraints limit long-term use in low-risk populations; may not reflect real-world prescribing.
Prospective Cohort StudyLevel 2bIn EvidenceThat individuals with HMGCR-inhibiting genotypes develop diabetes at higher rates over time without statin exposure.
That individuals with HMGCR-inhibiting genotypes develop diabetes at higher rates over time without statin exposure.
What This Would Prove
That individuals with HMGCR-inhibiting genotypes develop diabetes at higher rates over time without statin exposure.
Ideal Study Design
A prospective cohort of 15,000 adults aged 35–65 with HMGCR genotype data (rs17238484/rs12916), followed for 15 years with annual fasting glucose and diabetes diagnosis, excluding statin users.
Limitation: Cannot prove causality if other linked genes influence diabetes risk.
Evidence from Studies
Supporting (1)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
This study found that both genes that mimic statins and actual statin drugs raise diabetes risk by about 11–12%, and it’s because they block HMGCR — not just because they lower cholesterol. So yes, blocking HMGCR directly makes diabetes more likely.